IL6 and rheumatoid arthritis: Despite its anti-inflammatory effects in certain contexts, in RA, sCD40L contributes to monocyte activation, leading to the release of proinflammatory cytokines, including TNF and IL-6, which drive joint inflammation and tissue damage.